PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Clay B. Thorp

Ashutosh Chilkoti

PhaseBio Pharmaceuticals, Inc.

CataloniaBIO & HealthTech connects companies in the biotechnology and health sectors, facilitating collaboration and innovation in these areas.

CataloniaBIO & HealthTech

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities. 

Looking for a new role? Please visit our careers page to find out more about our open jobs and benefits at https://phasebio.com/careers/

Metric
Company Name	PhaseBio Pharmaceuticals, Inc.	CataloniaBIO & HealthTech
Symbol	PHAS
MSH ID	COM:PHASEBIO	HEALTH:CATALONIA
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	ES
Stage
Employee Count	60
Website	phasebio.com	catalonia.health
LinkedIn	phasebio-pharmaceuticals
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	10.83K
Revenue (LTM)
Revenue (NTM)
Gross Profit	10.83K
EBITDA	1.66M
Operating Income	-130.42K
Net Income	-131.07K
EPS	-0.00
Diluted EPS	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1
Operating Profit Margin	-12.04
EBITDA Margin	153.50
Net Profit Margin	-12.10
Return on Equity	0.00
Return on Assets	-0.00
Return on Capital Employed	-0.00

COM:PHASEBIO

PhaseBio Pharmaceuticals, Inc.

Last Close

0.07

17/09 20:00

Volume Today

8.56M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.12
P/B Ratio	-0.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple	20.42

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover	0.00

Metric
Operating Cash Flow	-47.42M
Free Cash Flow	-50.09M
Cash Flow to Debt	-6.04
Operating Cash Flow/Sales	-4.38K
Free Cash Flow Yield

Metric
Cash & Equivalents	41.80M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	-0.09
Debt to Assets	0.24
Current Ratio	0.47
Quick Ratio	1.50

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	4.04
R&D to Revenue	108.54
SG&A to Revenue	26.43